Diagnostic Kits/Competitive advantages in Kits: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) No edit summary |
AClearwater (talk | contribs) (penumbra effect and The Myriad Story) |
||
| Line 2: | Line 2: | ||
#Define the competitive advantages in the field and the barriers of entry | #Define the competitive advantages in the field and the barriers of entry | ||
'''penumbra effect''' | |||
* tests with genes in common lead to one lab having a functional monopoly over the group of diseases that require the common gene or mutation [http://cyber.law.harvard.edu/commonsbasedresearch/Diagnostic_Kits/The_dangers_of_diagnostic_monopolies Cook-Deegan et. al., 2009.] | |||
'''The Myriad Story''' | |||
*Patent-Mediated Standards in Genetic Testing | |||
==Navigation== | ==Navigation== | ||
Revision as of 12:54, 29 October 2009
Answer the questions:
- Define the competitive advantages in the field and the barriers of entry
penumbra effect
- tests with genes in common lead to one lab having a functional monopoly over the group of diseases that require the common gene or mutation Cook-Deegan et. al., 2009.
The Myriad Story
- Patent-Mediated Standards in Genetic Testing